ACN vs PACB · P/E 24, rev $17.60B vs rev $76.2M
Accenture plc (ACN) versus Pacific Biosciences of California (PACB) — a side-by-side from cached financials, not a winner call.
Accenture plc (ACN) is a information technology services company listed on US.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
Latest reported PACB revenue for 2026-06-30 was $76.2M. Net income was -$53.0M. PACB currently screens at market cap $387.1M.
ACN currently screens at market cap $186.16B and trailing P/E 23.8. PACB currently screens at market cap $387.1M.
Not investment advice. Open the ACN and PACB stock pages for the full models.
Not investment advice.